Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
22 Oktober 2024 - 2:00PM
Business Wire
Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage
biopharmaceutical company focused on advancing innovative
treatments for spinal muscular atrophy (SMA), cardiometabolic
disorders, and other serious diseases where protein growth factors
play a fundamental role, today announced that on October 16, 2024,
the underwriters of its previously announced underwritten public
offering of common stock and pre-funded warrants, which closed on
October 10, 2024, exercised their option in full to purchase an
additional 1,592,920 shares at the public offering price of $28.25
per share, resulting in additional gross proceeds of approximately
$45 million, before deducting underwriting discounts and
commissions and offering expenses payable by Scholar Rock. The
closing of the underwriters’ exercise of their option to purchase
1,592,920 additional shares occurred on October 18, 2024.
J.P. Morgan Securities LLC, Jefferies and Piper Sandler &
Co. acted as joint book-running managers for the offering. BMO
Capital Markets Corp., Wedbush Securities Inc. and Raymond James
& Associates, Inc. acted as co-managers for the offering.
An automatically effective shelf registration statement on Form
S-3 relating to the offering of the shares of common stock and
pre-funded warrants described above was filed with the Securities
and Exchange Commission (SEC) on October 7, 2024. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering were filed with the SEC on October 7, 2024, and are
available on the SEC’s website located at www.sec.gov. The final
prospectus supplement and accompanying prospectus relating to the
offering were filed with the SEC on October 9, 2023 and may be
obtained by contacting: J.P. Morgan Securities LLC, c/o: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by email at prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, New
York, NY 10022, by telephone at 877-821-7388, or by email at
prospectus_department@jefferies.com; or Piper Sandler & Co.,
800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention:
Prospectus Department, by telephone at 800-747-3924, or by email at
prospectus@psc.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
state or jurisdiction.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers,
develops, and delivers life-changing therapies for people with
serious diseases that have high unmet need. As a global leader in
the biology of the transforming growth factor beta (TGFβ)
superfamily of cell proteins and named for the visual resemblance
of a scholar rock to protein structures, the clinical-stage company
is focused on advancing innovative treatments where protein growth
factors are fundamental. Over the past decade, Scholar Rock has
created a pipeline with the potential to advance the standard of
care for neuromuscular disease, cardiometabolic disorders, cancer,
and other conditions where growth factor-targeted drugs can play a
transformational role.
This commitment to unlocking fundamentally different therapeutic
approaches is powered by broad application of a proprietary
platform, which has developed novel monoclonal antibodies to
modulate protein growth factors with extraordinary selectivity. By
harnessing cutting-edge science in disease spaces that are
historically under-addressed through traditional therapies, Scholar
Rock works every day to create new possibilities for patients.
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241022036032/en/
Scholar Rock: Investors Rushmie Nofsinger Scholar
Rock rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Media Molly MacLeod Scholar Rock mmacleod@scholarrock.com
media@scholarrock.com 802-579-5995
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
Von Dez 2023 bis Dez 2024